1 August 2017 - The August 2017 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes a number of major new/revised listings:

• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine (TYR Express 20) - new formulation
  
• Crizotinib (Xalkori) - restriction change (MES)
  
• Gonadotropin (human, chorionic) (Pregnyl) - new formulation
  
• Nivolumab (Opdivo) - new indication (renal cell carcinoma)
  
• Nivolumab (Opdivo) - new indication (non-small-cell lung cancer)
  
• Sofosbuvir with velpatasvir (Epclusa) - new combination product
  

Read summary of changes